Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Chao

Showing results (101-110 of 116) with videos related to

Pageof 12
Sort By:
Cancer Chemotherapy and Pharmacology|November 23, 2011
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium StudyJoseph Chao, Timothy W Synold, Robert J Morgan, et al.
British Journal of Cancer|December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinomaMichael Cecchini, James M Cleary, Yu Shyr, et al.
Annals of Surgical Oncology|July 27, 2023
Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USAMustafa Raoof, Richard L Whelan, Kevin M Sullivan, et al.
JAMA Oncology|April 1, 2021
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJoseph Chao, Charles S Fuchs, Kohei Shitara, et al.
Investigational New Drugs|February 12, 2013
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesGlen J Weiss, Joseph Chao, Jeffrey D Neidhart, et al.
Journal of Clinical Medicine|January 12, 2021
Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope ExperienceLinda D Bosserman, Mary Cianfrocca, Bertram Yuh, et al.
Cancers|July 2, 2021
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer PatientsMoom R Roosan, Isa Mambetsariev, Rebecca Pharaon, et al.
Nature Medicine|February 7, 2025
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A Reiss, Mathew G Angelos, E Claire Dees, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
JAMA Oncology|September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical TrialKohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Pageof 12

Showing results (101-110 of 116) with videos related to

Sort By:
Pageof 12
Cancer Chemotherapy and Pharmacology|November 23, 2011
A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium StudyJoseph Chao, Timothy W Synold, Robert J Morgan, et al.
British Journal of Cancer|December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinomaMichael Cecchini, James M Cleary, Yu Shyr, et al.
Annals of Surgical Oncology|July 27, 2023
Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USAMustafa Raoof, Richard L Whelan, Kevin M Sullivan, et al.
JAMA Oncology|April 1, 2021
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJoseph Chao, Charles S Fuchs, Kohei Shitara, et al.
Investigational New Drugs|February 12, 2013
First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignanciesGlen J Weiss, Joseph Chao, Jeffrey D Neidhart, et al.
Journal of Clinical Medicine|January 12, 2021
Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope ExperienceLinda D Bosserman, Mary Cianfrocca, Bertram Yuh, et al.
Cancers|July 2, 2021
Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer PatientsMoom R Roosan, Isa Mambetsariev, Rebecca Pharaon, et al.
Nature Medicine|February 7, 2025
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A Reiss, Mathew G Angelos, E Claire Dees, et al.
Journal for Immunotherapy of Cancer|February 3, 2022
Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancersGiovanni Fucà, Romain Cohen, Sara Lonardi, et al.
JAMA Oncology|September 4, 2020
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical TrialKohei Shitara, Eric Van Cutsem, Yung-Jue Bang, et al.
Pageof 12